Southeast Asia's Blood Glucose Monitoring Market Expected to Grow 11.75% to Reach USD Million by 2033, According to UnivDatos.

Key Highlights of the Report:

• The Southeast Asia blood glucose monitoring market is experiencing a robust growth driven by increased incidences of diabetes, the rise in self-monitoring glucose control, and continuous monitoring, as well as the spread of both self-monitoring and continuous monitoring technologies in urban and semi-urban healthcare systems.

• On a competitive level, multinational manufacturers are consolidating their regional presence by increasing their product portfolio, pricing, and distribution arrangements, and regional players are competing by offering lower prices and a localized supply model.

• The growth at the country level is still focused on Singapore and Indonesia, where the modernization of healthcare systems, the rise in the number of diabetics, and the widening access to services in the management of chronic diseases are still generating impressive business opportunities.

• Self-Monitoring Blood Glucose systems still lead in revenue share, with Continuous Glucose Monitoring systems becoming the fastest growing category with the increased use of connected and real-time monitoring systems.

• There is a rise in strategic alliances between device and hospital network, digital health provider and pharmacy distribution channel, and investment is shifting towards sensor innovation, mobile-integrated diabetes platform, and expansion into the underserved Southeast Asian consumer market.

According to a new report by UnivDatos, the Southeast Asia Blood Glucose Monitoring Market is expected to reach USD Million in 2033 by growing at a CAGR of 11.75% during the forecast period (2025- 2033F). The increase in the number of diabetics is due to urbanization, change of diet, obesity, and sedentary lifestyles. The growing healthcare spending, increased diabetes awareness, spreading diagnostic facilities, and the growing trend of managing diseases at home further boost demand. Moreover, governments in the region are strengthening chronic disease screening programs, driving up demand for routine glucose testing devices across both public and private healthcare systems.

Driver: Rising Prevalence of Cardiovascular Diseases

The rise in diabetes rates in Southeast Asia is a primary driver of growth in the blood glucose monitoring market, as the region continues to experience a steady increase in metabolic disorders due to urbanization, dietary habits, and sedentary lifestyles. Furthermore, the increasing incidence of diagnoses is leading to a new health care labor of patients and medical staff to the routine of monitoring their glucose levels as an indispensable element of clinical care and the prevention of complications. Moreover, increasing public awareness of the risks associated with diabetes promotes earlier testing, more frequent monitoring, and improved adherence to treatment. Also, there is an increase in product adoption in hospitals, clinics, and home-care facilities, as governments and healthcare organizations expand screening and education programs. The increased level of awareness is generating a long-term demand for both traditional glucometers and high-tech continuous monitoring devices.

As per the World Health Organization, in September 2025, in the WHO South-East Asia Region, nearly 246 million people aged 30 years and above are estimated to have diabetes. More than half of the people with diabetes are unaware of the condition. It is estimated that 68 million people with diabetes are on treatment, underlining the treatment gap of 177 million in the region. Diabetes is responsible for around 480,00 deaths annually in the Region.

Access sample report (including graphs, charts, and figures): https://univdatos.com/reports/southeast-asia-blood-glucose-monitoring-market?popup=report-enquiry

Segments that transform the industry

• Based on product type, the market is segmented into Self-Monitoring Blood Glucose (SMBG) Systems, Glucometers, which are sub-segmented into testing strips, lancets & lancing devices, and Continuous Glucose Monitoring (CGM) Systems, which are sub-segmented into sensors, transmitters, and receivers. Among these, the Continuous Glucose Monitoring (CGM) Systems market is expected to grow at a significant CAGR during the forecast period (2025-2033). This is mainly due to the introduction of real-time glucose monitoring and the minimization of dependence on frequent finger-prick testing. The growing awareness of urban diabetic populations led to increased adoption, while the integration of digital health technologies is advancing rapidly. Furthermore, companies are expanding their presence through sensor innovation, mobile app connectivity, and collaboration with hospitals and endocrinology centers. For example, on August 7, 2024, Abbott announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott's most advanced, world-leading FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems. The integration of Abbott's CGM sensor with Medtronic's AID algorithms will enable automatic adjustments of insulin to keep glucose in range. The CGM sensor, designed to work exclusively with Medtronic devices, will be developed by Abbott and sold by Medtronic.

Region that transforms the industry

• Indonesia is expected to grow at a significant CAGR during the forecast period (2025-2033). This is mainly due to the rising prevalence of diabetes, an increasing middle-income population, and the accessibility of primary healthcare services that drive the market. The surge in urbanization and diabetes cases driven by lifestyle changes is increasing demand for affordable blood glucose monitors in big cities and secondary health facilities. In addition, the companies are targeting low-cost glucometers and broader pharmacy distribution to tap demand in price-sensitive markets. Also, the adoption is being supported by government efforts to enhance community health centers' diagnosis of chronic diseases. Moreover, the growth is also being fueled by the increase in home-based monitoring of diabetes, especially among elderly patients and long-term diabetics. For example, on December 24, 2025, Daewoong Pharmaceutical (hereinafter “Daewoong”) announced that it had officially obtained marketing authorization from Indonesia’s National Agency of Drug and Food Control (BPOM) for its new diabetes drug, Enavogliflozin.

Key Offerings of the Report

Market Size, Trends, & Forecast by Revenue | 2025−2033.

Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities

Market Segmentation – A detailed analysis of By Product Type, By Application, By End-User, By Country

Competitive Landscape – Top Key Vendors and Other Prominent Vendors